What will happen to free pricing and Orphan Drugs in Germany after the election?
By Jens Leutloff, Senior Consultant Email jleutloff@partner4access.com The discussion of cost containment measures in the German healthcare system does not seem to stop, and could gain new momentum after Germany’s federal election in September. Once again, the idea to shorten the free pricing period in Germany was raised recently. During a virtual event celebrating 10…